Immunic Q3 2023 Earnings Report
Key Takeaways
Immunic reported progress in the clinical development of vidofludimus calcium, including positive interim biomarker analysis from the phase 2 CALLIPER trial in progressive multiple sclerosis. The company's cash and cash equivalents were $59.7 million as of September 30, 2023, which is expected to fund operations into September 2024.
Positive interim analysis from Phase 2 CALLIPER trial showed improvements in serum neurofilament light chain for vidofludimus calcium.
Notice of allowance for United States patent protecting the treatment of relapsing multiple sclerosis with vidofludimus and its salts was received.
Enrollment was completed in the phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS).
Cash and cash equivalents totaled $59.7 million as of September 30, 2023, expected to fund Immunic into September of 2024.
Immunic
Immunic
Forward Guidance
Immunic anticipates several clinical milestones, including reporting top-line CALLIPER data in April 2025 and an interim futility analysis for the ENSURE program in late 2024.
Positive Outlook
- Potential positioning of vidofludimus calcium as the first oral treatment for non-active secondary progressive MS.
- Potential first-in-class ability of the drug to activate Nurr1 may meaningfully benefit the ongoing phase 3 ENSURE program in relapsing MS (RMS).
- Phase 3 ENSURE trials are ongoing, with an interim futility analysis expected in late 2024.
- Read-out of the first of the ENSURE trials expected at the end of 2025.
- Vidofludimus calcium, with combined neuroprotective, anti-inflammatory, and antiviral effects, could potentially offer a unique treatment option targeted to the complex pathophysiology of MS.